The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage

Semin Ophthalmol. 2015 May;30(3):177-80. doi: 10.3109/08820538.2013.835847. Epub 2014 Jan 10.

Abstract

Purpose: This study was constructed to compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection.

Methods: It is a retrospective chart review of all patients who had undergone PPV for diabetic VH from January 2008 to January 2011. Patients who had undergone IVB injection before PPV were assigned to Group 1; the others were assigned to Group 2. Postoperative VH was the main outcome.

Results: A total of 65 eyes of 60 patients (19 eyes in Group 1 and 46 eyes in Group 2) were examined. Postoperative VH occured in three eyes (15.8%) in Group 1 and in 13 eyes (28.3%) in Group 2, but this was not statistically significant (p: 0.347).

Conclusion: Further studies to evaluate the effect of IVB on postoperative VH are needed.

Keywords: Bevacizumab; Proliferative diabetic retinopathy; intravitreal injection; vitrectomy; vitreous hemorrhage.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Combined Modality Therapy
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / etiology
  • Diabetic Retinopathy / surgery
  • Diabetic Retinopathy / therapy*
  • Female
  • Humans
  • Incidence
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Postoperative Complications
  • Recurrence
  • Retrospective Studies
  • Severity of Illness Index
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Vitrectomy*
  • Vitreous Hemorrhage / drug therapy
  • Vitreous Hemorrhage / etiology
  • Vitreous Hemorrhage / surgery
  • Vitreous Hemorrhage / therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab